Variations and clinical significance of coagulation and fibrinolysis parameters in patients with diabetes mellitus

Abstract

We observed the changes of parameters of coagulation and fibrinolytic system in order to understand the clinical implication of these variations in type I diabetic patients. Subjects consisted of 22 patients with type I diabetes mellitus and 25 healthy controls. Compared with the control, activated partial thromboplastin time, prothrombin time were shortened in the patients. The diabetic subjects also displayed higher levels of D-dimer, serum fibrin degradation products, median concentrations of fibrinogen (3. 99 vs 2. 96 g/L,P<0. 01) and von Willebrand factor (149 % vs 87 %,P<0.01). Levels of antithrombin activity or antigen were not different from control values. Simple linear regression analysis revealed a negative correlation between antithrombin activity and fast blood glucose. Diabetic patients with vascular complications had significantly higher levels of fibrinogen and D-dimer than those without diabetic angiopathy. Our data demonstrated that patients with type I diabetes mellitus had a hypercoagulable state. We believed the activation of coagulation might contribute to the vascular complications in diabetics.

Keywords

diabetes mellitus / hypercoagulability / vascular complication

References

[1] CortellaroM, BoschettiC, CofrancescoE. The PLAT study: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients. Atherosclerosis, 1991, 90109-109

[2] ColwellJ A. Vascular thrombosis in type I diabetes mellitus. Diabetes, 1993, 428-8

[3] 1991, 14:351

[4] GreenburgC S, DevineD V, McGraeK M. Measurement of plasma fibrin D-dimer levels with the use of a monoclonal antibody coupled to latex beads. Am J Clin Path, 1986, 8794-94

[5] KnoblP, SchernthanerG, SchnackC, et al. . Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type diabetic patients. Thromb Haemost, 1994, 71692-692

[6] CarmassiF, MoraleM, PuccettiR, et al. . Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res, 1992, 67643-643

[7] LeeA J, LowG D O, WoodardM, et al. . Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J, 1993, 69338-338

[8] FalletiE. Fibrinogen plasma levels as a marker of thrombin activation: new insights of the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost, 1994, 71593-593

[9] CerielloA, TabogaC, GiacomelloR, et al. . Fibringoen plasma levels as a marker of thrombin activation in diabetes. Diabetes, 1994, 43430-430

[10] TripodiA, MannucciP M. Markers of activated coagulation and their usefulness in the clinical laboratory. Clin Chem, 1996, 42664-664